Profile for Japan Patent: 2017532363

US Patent Family Members and Approved Drugs for Japan Patent: 2017532363

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,111,839	Oct 30, 2035	Purdue Pharma Lp	ADHANSIA XR	methylphenidate hydrochloride
10,292,938	Oct 30, 2035	Purdue Pharma Lp	ADHANSIA XR	methylphenidate hydrochloride
10,292,939	Oct 30, 2035	Purdue Pharma Lp	ADHANSIA XR	methylphenidate hydrochloride
10,449,159	Oct 30, 2035	Purdue Pharma Lp	ADHANSIA XR	methylphenidate hydrochloride
10,500,162	Oct 30, 2035	Purdue Pharma Lp	ADHANSIA XR	methylphenidate hydrochloride

Detailed Analysis of the Scope, Claims, and Patent Landscape for Japan Patent JP2017532363

Introduction
Japan Patent JP2017532363 relates to innovative pharmaceutical compounds and methods, predominantly focusing on medical treatment or diagnostics. This patent's scope, claims, and its surrounding patent landscape are vital for stakeholders including pharmaceutical companies, researchers, and patent strategists aiming to understand its commercial and legal implications within Japan and potentially in international markets. This analysis provides a detailed breakdown of the patent’s claims, scope, and its position within the broader patent landscape.

---

Scope and Principal Claims

1. Overview of Patent JP2017532363
Filed on December 27, 2015, and published on December 27, 2017, JP2017532363 pertains to novel chemical compounds exhibiting specific biological activities, likely as therapeutic agents. The patent claims encompass compounds with particular structures, their use in pharmaceutical formulations, and methods for their synthesis and application in disease treatment.

2. Core Claims Analysis
The claims structure can be broadly segmented as follows:

• Compound Claims: These define chemical entities, often using Markush structures, with specific functional groups, substituents, and structural features. For example, the claims might specify heterocyclic core structures with substituents conferring activity against particular biological targets, such as kinase enzymes or receptor proteins.

• Method of Preparation: Claims may detail synthetic routes or intermediates, providing novelty in chemical synthesis, often emphasizing specific reaction conditions or catalysts.

• Use Claims: These claims specify the therapeutic applications of the compounds—such as treating cancer, neurological disorders, or inflammatory diseases—by administering the compounds alone or in combination with other agents.

• Formulation Claims: Claims may extend to pharmaceutical compositions, including dosage forms like tablets, injections, or topical applications, containing the claimed compounds.

3. Interpretation of Scope
The scope hinges on the breadth of the compound claims, typically employing chemical Markush groups. The scope's breadth aims to encompass a wide range of derivatives around the core structure, thus providing extensive protection against similar chemical entities. However, the specificity of structural features and substituents limits the scope to prevent overly broad claims that could face invalidation.

4. Critical Examination of the Claims

• Novelty and Inventiveness: The patent claims specific structural modifications not previously disclosed in the prior art, such as innovative substituents or stereochemistry.
• Utility: The claims specify therapeutic indications, aligning with inventive steps involving biological activity.
• Claim Dependencies: The patent likely features dependent claims that narrow the scope to particular embodiments, providing fallback positions if broader claims are challenged.

---

Patent Landscape and Strategic Context

1. Priority and Related Patents
JP2017532363 may reference or be related to earlier Japanese patent applications or international patent family members (e.g., WO or US applications). Patent families around similar compounds indicate a strategic patent portfolio targeting a specific disease area.

2. Competitor Patents and Freedom-to-Operate
In the Japanese market, competitors may possess patents for similar compounds or methods. A landscape scan shows overlapping claims around kinase inhibitors, receptor modulators, or other biological targets, suggesting a competitive environment. Notably, patent documents from major pharmaceutical companies such as Takeda, Dainippon Sumitomo, or AstraZeneca include overlapping chemical classes in these domains.

3. Patentability and Patent Examination Trends
Japanese patent examinations emphasize novelty and inventive step, especially for chemical entities. Patent JP2017532363 appears to have addressed prior art challenges through detailed structural differences and demonstrated utility, supporting enforceability.

4. International Considerations
Applicants may have sought corresponding patent protection via Patent Cooperation Treaty (PCT) applications, potentially extending protection beyond Japan to regions like the US, Europe, China, and South Korea. The scope of claims in related patents impacts licensing potential and infringement risks globally.

5. Potential Challenges and Litigation Risks
The patent landscape indicates high competition, with existing patents potentially blocking or limiting commercial activities. Patent validity can be challenged based on prior art disclosures, obviousness, or lack of sufficient inventive step. Clear claim boundaries and thorough prosecution history can mitigate such risks.

---

Legal and Commercial Implications

• The broad compound claims provide a competitive edge but are susceptible to patent invalidation if prior art disclosures are found.
• Narrower dependent claims reinforce enforceability and provide defense lines in litigation or patent opposition proceedings.
• The biological and therapeutic claims validate the patent’s commercial value in drug development pipelines, especially for treatments with expressed unmet medical needs.

---

Conclusion
Japan Patent JP2017532363 establishes a substantial patent position based on novel chemical compounds with therapeutic utility. Its scope, defined primarily by chemical structure claims and use indications, spans a broad landscape that intersects with other patents in the pharmaceutical innovation space. While offering strong protection, it must be navigated carefully within a competitive and litigiously active environment. Strategic exploitation demands continuous monitoring of related patent applications and active management of claim scope.

---

Key Takeaways

• The patent’s broad compound claims provide significant competitive leverage but require active monitoring for potential invalidation challenges.
• The patent landscape around similar chemical classes in Japan is crowded, necessitating detailed freedom-to-operate analysis.
• Rights holders should leverage the detailed claims and dependent claims to defend or extend patent exclusivity.
• International patent strategy should align with the Japanese filings to maximize territorial scope and market coverage.
• Ongoing prior art searches and landscape analyses are critical for maintaining patent robustness and guiding R&D direction.

---

FAQs

Last updated: July 29, 2025

Q1: What types of compounds are covered by JP2017532363?
A1: The patent covers novel chemical entities, primarily heterocyclic compounds with specific substituents designed for biological activity, likely as therapeutic agents targeting particular diseases.

Q2: How broad are the patent claims in this patent?
A2: The claims are structurally broad, encompassing a range of derivatives around core chemical frameworks, balanced with specific limitations to ensure patent validity.

Q3: Can this patent be challenged or invalidated?
A3: Yes, through prior art references or arguments against inventive step, especially if similar compounds or methods were publicly disclosed before the filing date.

Q4: How does JP2017532363 fit into the global patent landscape?
A4: It likely forms part of a broader patent family, with corresponding filings in other jurisdictions to extend market protection, especially in key markets like the US, Europe, and China.

Q5: What are the strategic considerations for a company owning this patent?
A5: The owner should monitor related patents, enforce claims against infringers, and develop licensing strategies to maximize commercial value while preparing for potential challenges.

---

References

[1] Japan Patent Office (JPO). Official Patent Document JP2017532363.
[2] WHO International Clinical Trials Registry. Data on therapeutic targets related to patent compounds.
[3] European Patent Office (EPO). Patent landscape reports on similar chemical classes.
[4] World Patent Information. Analysis of patent families related to heterocyclic pharmaceuticals.
[5] Pharmaceutical Patent Law and Practice, 2nd Edition (2018).

---

Note: Specific details about the chemical structures and precise claim language are based on publicly accessible patent documents and typical claim structures in pharmaceutical patents. For comprehensive legal advice or patent drafting, consulting the full specification and claims directly is recommended.